Current Clinical Trial Evidence for ICS-Based Therapy in Patients with COPD
| Characteristics of Patients with COPD | References |
|---|---|
| Patients with coexistent asthma or asthma history | Lim et al, 201484 |
| Pascoe et al, 201556 | |
| Ishiura et al, 201553 | |
| Lee et al, 2016 (KOLD)54 | |
| Lipson et al, 2018 (IMPACT)51 | |
| Patients with eosinophils <600 cells/µL | Roche et al, 2017 (FLAME)27 |
| Chapman et al, 2018 (SUNSET)85 | |
| Patients on LABA/LAMA who continue to exacerbate | Singh et al, 2016 (TRILOGY)67 |
| Vestbo et al, 2017 (TRINITY)70 | |
| Lipson et al, 2017 (FULFIL)65 | |
| Papi et al, 2018 (TRIBUTE)71 | |
| Halpin et al, 2018 (FULFIL)86 | |
| Patients with eosinophils ≥300 cells/µL and a history of ≥ 1 exacerbation in previous year | Watz et al, 2016 (WISDOM)77 |
| Wedzicha et al, 2016 (FLAME)29 | |
| Calverley et al, 2017 (WISDOM)76 | |
| Papi et al, 2018 (FLAME)87 | |
| Chapman et al, 2018 (SUNSET)85 | |
| Anzueto et al, 2018 (FLAME)88 | |
| Patients with severe COPD and recalcitrant symptoms | Bourbeau et al, 201719 |
COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting antimuscarinic antagonist.